AUTHORS
Wei Ying Jen, BM BCh, FRCPath, Ghayas C. Issa, MD2, Naval Daver, MD3, Wei Qiao4, Tapan Kadia I, MD5, Nicholas Short, MD6, Elizabeth A Griffiths, MD7, James Thompson, M.D., M.S.8, Pamela J. Sung, MD PhD9, Alexandre Bazinet, MD10, Abhishek Maiti, MBBS11, Eitan Kugler, MD PhD12, Ian Bouligny, M.D.13, Jennifer Marvin-Peek, MD14, Koichi Takahashi, MD,PhD15, Farhad Ravandi, MD16, Guillermo Garcia-Manero, MD17, Courtney DiNardo, MD, MSCE18, Eunice Sue Wang, MD19
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
8 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
18 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
19 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
ABSTRACT
Study Rationale
Patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) have a dismal prognosis, with a median overall survival (OS) of 5-6 months and complete remission (CR) rates of approximately 15% when treated with standard cytotoxic therapy. Nucleophosmin-1 mutations (NPM1mt) are present in approximately 30% of all newly diagnosed AML and are susceptible to menin inhibition through disruption of the menin-KMT2A interaction. In the KOMET-001 study, treatment with ziftomenib monotherapy resulted in CR rates of 22% in R/R NPM1mt AML with median OS of 6.6 months. These findings suggest that additional, non-NPM1mt-dependent resistance mechanisms may contribute to disease persistence or progression and could provide a rationale for combination treatment strategies. Up to 20% of NPM1mt AML harbor co-existent IDH1 mutations (IDH1mt). Olutasidenib is a potent second-generation IDH1 inhibitor which results in CR/CRh rates of 35% in R/R IDH1mt AML with a median duration of response of 23.5 months those with CR/CRh. The presence of both NPM1 and IDH1 co-mutations in the same AML cells may contribute to leukemogenesis via disparate pathways. We hypothesized that treating patients with R/R AML characterized by co-mutations in NPM1 and IDH1 with dual targeted inhibitors, ziftomenib and olutasidenib, could improve efficacy over either monotherapy.
Design and Methods
This phase 1/1b study (NCT07411586) is a multi-center, open-label, non-randomized clinical trial investigating the oral combination of ziftomenib and olutasidenib in adult patients with NPM1mt and IDH1mt R/R AML. Patients with prior exposure to ziftomenib or olutasidenib will not be eligible, although those treated with other menin or IDH inhibitors may enroll on the study.
The primary endpoints are: to determine the safety and tolerability and recommended phase 2 dose (RP2D) of ziftomenib and olutasidenib (phase 1); to evaluate the preliminary efficacy and additional safety of the combination therapy (phase 1b). Secondary objectives include determination of the composite CR rate (CRc), overall response rate, measurable residual disease CR/CRc rate, time to achieve CR/CRh and CRc, transfusion independence, rate of subsequent allogeneic stem cell transplant (SCT), and changes in longitudinal IDH1mt variant allele fraction.
Treatment will comprise 28-day cycles of concomitant ziftomenib and olutasidenib. All patients will receive olutasidenib 150mg orally twice daily. Dose escalation of ziftomenib is planned using a standard 3+3 design, beginning with dose level 1 (DL1) of 400mg orally daily and escalating to a target dose level 2 (DL2) of 600mg daily based on tolerability. If excessive toxicity is noted, reduction of ziftomenib to a minus 1 (DL-1) dose level of 200 mg daily will be explored.
Patients treated on this study will be specifically monitored for any increased rate and/or severity of clinical differentiation syndrome (DS), given that both olutasidenib and ziftomenib monotherapy are associated with DS. Subjects at high risk of DS (defined as a baseline white cell count >5x109/L, known extramedullary disease involving ≥2 sites or a single mass >5cm, or requiring cytoreduction prior to starting therapy to maintain a WBC <25x109/L), will receive protocol mandated prophylactic steroids (0.5mg/kg prednisone or equivalent) for a minimum of 14 days.
After determination of the ziftomenib RP2D, additional patients will be treated at the ziftomenib RP2D in combination with olutasidenib to further evaluate the preliminary clinical efficacy of this dual oral inhibitor approach for R/R AML. A maximum of 32 patients in both phase 1 and 1b portions will be treated for a minimum of four 28-day cycles of combination therapy unless there is evidence of relapse, non-response, or known SCT.
This study is currently enrolling patients at The University of Texas MD Anderson Cancer Center, Houston, TX, and is planned to accrue at Roswell Park Comprehensive Cancer Center, in Buffalo, NY, and additional planned centers in the United States.
Conclusion
In summary, this phase 1/1b trial will establish the safety, tolerability, and preliminary efficacy of the combination of the mutant IDH1 inhibitor, olutasidenib, and the menin inhibitor, ziftomenib, for treatment of adult patients with R/R AML harboring co-mutations in IDH1 and NPM1.
DISCLOSURES
Wei Ying Jen, BM BCh, FRCPath: No relevant conflicts of interest to declare.